The current dermatology pipeline includes a wide range of medication classes, from Janus kinase (JAK) inhibitors to tumor necrosis factor inhibitors, to phototherapeutics. At the 2023 American Society of Health-System Pharmacists (ASHP) Summer Meetings and Exhibition,1 Courtney Queen, PharmD, CSP, of the University of Kentucky Specialty Pharmacy and Infusion Services in Lexington, Kentucky, shared a quick snapshot of some of that pipeline. Although only 4 conditions were covered—chosen due to the high number of agents in the pipeline—Queen noted that “there are so many more [drugs] we could talk about.”